Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

582
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
582
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

410
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
410
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

608
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
608
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

440
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
440
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

460
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
460

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Implications of Poststroke Aphasia: A Multicenter Cohort Study in Tertiary Hospitals.

Journal of the American Heart Association·2026
Same author

Lateropulsion and visual vertical tilt after supra- and infratentorial stroke: a longitudinal study.

Annals of physical and rehabilitation medicine·2026
Same author

PyCaret machine learning library with three preprocessing steps after eLORETA source estimation predicts Alzheimer's disease.

Neuroimage. Reports·2026
Same author

Gait and frontal lobe function become associated in patients with idiopathic normal pressure hydrocephalus after shunt surgery.

Frontiers in neurology·2025
Same author

Gait Improvement Following CSF Tap Test in NPH Patients With and Without Striatal Dopaminergic Deficit: A Preliminary Study.

Neurology. Clinical practice·2025
Same author

Effect of Inpatient Cardiac Rehabilitation Combined with Waon Therapy on Exercise Capacity in Elderly Patients with Heart Failure: A Pilot Study.

Physical therapy research·2025
Same journal

P2Y12-P-selectin-mediated platelet activation in a murine model of dengue-associated thrombocytopenia.

EBioMedicine·2026
Same journal

Inosine accumulation in hydrosalpinx fluid: a metabolic barrier to early embryonic development.

EBioMedicine·2026
Same journal

Multi-modal single-cell sequencing reveals network transition in circulating monocytes that aligns with faster recovery in patients with trauma and favours a response to M-CSF.

EBioMedicine·2026
Same journal

HCV-specific CD4<sup>+</sup> T-cells are susceptible to HIV-1 and contribute to viral persistence during antiretroviral therapy.

EBioMedicine·2026
Same journal

Effects of exercise and exercise timing on energy intake and appetite control: a randomised crossover trial in people with overweight or obesity with and without type 2 diabetes.

EBioMedicine·2026
Same journal

Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primates.

EBioMedicine·2026
See all related articles

Related Experiment Video

Updated: Mar 31, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.8K

The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group

Naohisa Hosomi1, Yoji Nagai2, Tatsuo Kohriyama3

  • 1Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.

Ebiomedicine
|October 27, 2015
PubMed
Summary
This summary is machine-generated.

Low-dose pravastatin may reduce recurrent stroke caused by large artery atherosclerosis in Asian patients. Further research is needed to confirm its effectiveness for total stroke and transient ischemic attack (TIA) prevention.

Keywords:
Atherothrombotic infarctionCholesterolHemorrhagic strokeIschemic strokeStatin

More Related Videos

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

2.0K
The Stroke Preclinical Assessment Network Multi-laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
05:46

The Stroke Preclinical Assessment Network Multi-laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

387

Related Experiment Videos

Last Updated: Mar 31, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.8K
Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

2.0K
The Stroke Preclinical Assessment Network Multi-laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
05:46

The Stroke Preclinical Assessment Network Multi-laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

387

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Clinical Pharmacology

Background:

  • Statin therapy benefits initial stroke prevention, but its role in preventing recurrent stroke and subtypes in Asian populations remains unclear.
  • Asian stroke profiles differ from Caucasian, necessitating specific research on stroke recurrence prevention.
  • This study investigated the efficacy of low-dose pravastatin in preventing recurrent ischemic stroke in Asian patients.

Purpose of the Study:

  • To determine if low-dose pravastatin (10 mg/day) can prevent stroke recurrence in patients with a history of non-cardioembolic ischemic stroke.
  • To examine the effect of pravastatin on the incidence of specific stroke subtypes.
  • To evaluate the safety and tolerability of low-dose pravastatin in this patient cohort.

Main Methods:

  • A multicenter, randomized, open-label, blinded-endpoint, parallel-group study.
  • Recruited 1578 patients with ischemic stroke and total cholesterol between 4.65-6.21 mmol/L, not on statins.
  • Patients received either 10 mg pravastatin daily or no statin, with stroke and transient ischemic attack (TIA) as primary endpoints.

Main Results:

  • During a mean follow-up of 4.9 years, total stroke and TIA rates were similar between groups (2.56% vs. 2.65%/year).
  • Pravastatin significantly reduced the onset of atherothrombotic infarction (0.21% vs. 0.64%/year, P=0.0047).
  • No significant differences were observed in other stroke subtypes or adverse events between the pravastatin and control groups.

Conclusions:

  • Low-dose pravastatin may reduce stroke recurrence due to large artery atherosclerosis in Asian ischemic stroke patients.
  • Further studies are required to confirm the preventive effect of low-dose pravastatin on total stroke and TIA recurrence in this population.
  • The findings generate a hypothesis for targeted stroke prevention strategies in specific Asian patient groups.